Coverage
-
May 12, 2015
A California federal judge signed off on a deal Tuesday to resolve claims brought by a unit of Par Pharmaceutical Inc. accusing Hospira Inc. of falsely marketing its products as being comparable to Par's FDA-approved version of the allergy treatment epinephrine.
2 other articles on this case.
View all »